IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
312.52
+1.81 (+0.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close310.71
Open311.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range311.00 - 312.82
52 Week Range261.65 - 342.50
Volume519,070
Avg. Volume958,444
Net Assets9.58B
NAV314.12
PE Ratio (TTM)10.86
Yield0.22%
YTD Return18.62%
Beta (3y)1.30
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • Yahoo Finance Contributors6 days ago

    Stock Market Video Analysis 11/17/17

  • Yahoo Finance Contributorslast month

    Stock Market Video Analysis 10/20/17

  • Why the Broadcom bid for Qualcomm may end in a proxy battle
    Yahoo Finance Video17 days ago

    Why the Broadcom bid for Qualcomm may end in a proxy battle

    Broadcom made an unsolicited bid for Qualcomm early Monday. The $70 a share offer values the deal at a whopping $130 billion. Yahoo Finance's Alexis Christoforous and Jared Blikre discuss what are the odds this deal will get regulatory approval, and what it could mean for the chip industry.

  • Can the markets continue record run?
    CNBC Videos27 days ago

    Can the markets continue record run?

    Sean O'Hara, president of Pacer ETF Distributors, and CNBC Contributor Ron Insana discuss a record-breaking year in the markets.

  • "Fast Money" final trades: BAC, IBB and more
    CNBC Videos29 days ago

    "Fast Money" final trades: BAC, IBB and more

    The “Fast Money” traders share their final trades for the day including Bank of America, Nasdaq Biotechnology ETF, MSCI Emerging Markets ETF and Alphabet.

  • Despite Amgen's earnings beat, one technician says Amgen ...
    CNBC Videos29 days ago

    Despite Amgen's earnings beat, one technician says Amgen ...

    Carter Worth, Cornerstone Macro, discusses how to keep betting on biotech.

  • This app gets you facetime with your physician
    Yahoo Finance Video29 days ago

    This app gets you facetime with your physician

    Better and faster care. It’s what we want from our doctors and healthcare providers. And new technology is finally starting to solve some of the most frustrating problems doctors and patients have. Yahoo Finance's Alexis Christoforous and Michael Keoni DeFranco, CEO of Lua, discuss.

  • Mnuchin: markets will tank without tax reform
    Yahoo Finance Videolast month

    Mnuchin: markets will tank without tax reform

    The treasury secretary gave an ’absolute guarantee' that a tax overhaul would be signed into law by the end of the year. Yahoo Finance’s Alexis Christoforous, Dan Roberts, and Kevin Mahn, CIO of Hennion & Walsh Asset Management discuss whether or not investors should trust Mnuchin’s tax prediction.

  • Technician says this one hot sector is about to heat up
    CNBC Videoslast month

    Technician says this one hot sector is about to heat up

    Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.

  • Health care stocks fall on Trump's comments
    CNBC Videoslast month

    Health care stocks fall on Trump's comments

    CNBC's Meg Tirrell reports on President Trump's comments on health insurers during a Cabinet meeting sending insurance stocks down.

  • Investors are NOT too optimistic right now: NYSE trader
    Yahoo Finance Videolast month

    Investors are NOT too optimistic right now: NYSE trader

    Alan Valdes, Director of Floor Operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss Q3 earnings and if investors have gotten too optimistic.

  • CA governor expected to sign drug pricing bill today
    CNBC Videoslast month

    CA governor expected to sign drug pricing bill today

    CNBC's Meg Tirrell reports on California's proposed bill requiring companies to give 60 days notice in advance when they plan to raise drug prices over a certain threshold.

  • Investopedia6 days ago

    Biotech Funds Flashing Sell Signals

    Biotech funds are testing mid-year breakouts after selling off to two-month lows and could break down in coming weeks.

  • Trade of the Day: Celgene Corporation Attempts a Breakout
    InvestorPlace6 days ago

    Trade of the Day: Celgene Corporation Attempts a Breakout

    Shares of large-cap biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) rallied on Thursday  as a broader risk-on feel came back to the world of U.S. equities. As regular readers of this column know, higher-volatility groups of stocks and in particular biotechnology in my eye are better traded using an ETF to represent the group thematically. While I continue to like biotechnology and the IBB ETF thematically, through a multi-month lens, I don’t so much like to a) buy them at the top end of their trading ranges and b) don’t like all stocks in this space at any price.

  • Investopedia8 days ago

    Biotech Alkermes Could Jump On Opioid Treatment Sales

    The company's sales could explode it its opioid treatment is successful

  • Did iShares Trust – iShares Nasdaq Biotechnology ETF (IBB) Create Value For Investors Over The Past Year?
    Simply Wall St.8 days ago

    Did iShares Trust – iShares Nasdaq Biotechnology ETF (IBB) Create Value For Investors Over The Past Year?

    iShares Trust – iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) generated a below-average return on equity of 11.11% in the past 12 months, while its industry returned 11.73%. An investor may attributeRead More...

  • Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
    Investor's Business Daily9 days ago

    Biotechs Sell Off In Droves — Are Investors Seeking Mergers?

    Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.

  • Investopedia9 days ago

    Why Biotech Stocks Are Nearing a Rebound

    Biotechnology stocks may be on the rise after a month-long downward shift.

  • Mixed Prognosis for Healthcare Stocks
    InvestorPlace10 days ago

    Mixed Prognosis for Healthcare Stocks

    If someone had told you at the beginning of the year that the Republican-controlled Congress was going to try and fail to repeal and replace the Affordable Care Act (ACA) multiple times during 2017, you probably wouldn’t have believed them. You might think that this uncertainty would have taken a bearish toll on healthcare stocks, but you’d be wrong in most cases. Many healthcare stocks are keeping pace with, or outperforming, the S&P 500.

  • Benzinga15 days ago

    A Big Biotech ETF Is About To Get Cheaper

    A big biotechnology exchange traded fund will soon get a lower price tag. BlackRock Inc. (NYSE: BLK ), the parent company of iShares, the world's largest ETF sponsor, announced a share split for the iShares ...

  • MarketWatch15 days ago

    Regeneron's stock rallies after profit and sales rise above expectations

    Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased ...

  • It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
    InvestorPlacelast month

    It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock

    Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.

  • Investopedialast month

    Celgene, Biogen Are Poised to Break Out: A Technical View

    After a period of consolidation, the biotech sector is set to rise again based on technical analysis.

  • Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow
    InvestorPlacelast month

    Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow

    Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.

  • No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock
    InvestorPlace2 months ago

    No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock

    Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline. To do this, I use CELG options instead of trading its underlying equity. Click to Enlarge Fundamentally, Celgene is not cheap.